Alumis (ALMS) closed at $6.03 on November 6, 2026, up 3.1% from the previous close, on volume of 1,199,100 shares (30-day average 1,967,735).
Data as of November 6, 2026.
6-Nov-2026
| # | Date | Strategy | Legs | Contracts |
|---|---|---|---|---|
| 1 | Oct 30, 2026 | Call Spread | 21-Jan-287 : 12 C | 600 |
| 2-3 | The next 2 largest trades are for Premium members. Start a 7-day free trial | |||
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 6, 2026. See the 10 largest for 30, 60 and 90 days
Globe Newswire (Fri, 9-Oct 4:00 AM ET)
Alumis to Participate in Upcoming September Investor Conferences
Globe Newswire (Fri, 4-Sep 8:00 AM ET)
Globe Newswire (Tue, 1-Sep 7:30 AM ET)
Alumis Reports Second Quarter 2026 Financial Results and Highlights Recent Achievements
Globe Newswire (Thu, 13-Aug 4:01 PM ET)
Globe Newswire (Mon, 10-Aug 4:05 PM ET)
Market Chameleon (Fri, 15-May 6:38 AM ET)
Market Chameleon (Thu, 8-Jan 2:53 AM ET)
Market Chameleon (Tue, 6-Jan 4:52 AM ET)
Alumis Inc is a clinical-stage biopharmaceutical company with an initial focus on developing its two Tyrosine Kinase 2 ("TYK2") inhibitors: envudeucitinib ("envu"), an allosteric TYK2 inhibitor for the treatment of PsO and SLE; and A-005, a central nervous system ("CNS") penetrant allosteric TYK2 inhibitor, to offer the therapeutic benefit of TYK2 inhibition within the CNS for a broad range of neuroinflammatory and neurodegenerative diseases.
Alumis trades on the NASDAQ stock market under the symbol ALMS.
As of November 6, 2026, ALMS stock price climbed to $6.03 with 1,199,100 million shares trading.
ALMS has a beta of 1.35, meaning it tends to be more sensitive to market movements. ALMS has a correlation of 0.02 to the broad based SPY ETF.
ALMS has a market cap of $780.49 million. This is considered a Small Cap stock.
Last quarter Alumis reported $2 million in Revenue and -$1.11 earnings per share. This fell short of revenue expectation by $-2 million and missed earnings estimates by -$.40.
The top ETF exchange traded funds that ALMS belongs to (by Net Assets): VTI, IWM, VXF, XPH, IWO.
ALMS has outperformed the market in the last year with a return of +27.8%, while the SPY ETF gained +10.8%. However, in the most recent history, ALMS shares have underperformed the stock market with its stock returning -78.3% in the last 3 month period and -11.1% for the last 2 week period, while SPY has returned -4.1% and -3.2%, respectively.
ALMS support price is $5.57 and resistance is $6.13 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ALMS shares will trade within this expected range on the day.
